• FDA Lifts Hold on Multiple Myeloma Study americanpharmaceuticalreview
    December 03, 2020
    Cellectis announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM).
PharmaSources Customer Service